News

Non-motor Symptoms Determine Quality of Life After DBS

Non-motor symptoms are major determinants of quality of life (QOL) for people with Parkinson’s disease who have undergone deep brain stimulation, known as DBS, a new study reports. “Postoperative QOL was associated with non-motor symptoms … rather than motor symptoms,” the researchers found, specifically noting that patients with…

New Rasagiline Formulation May Allow Application to Skin

A new formulation of rasagiline, approved for Parkinson’s disease, may allow the therapy to be given by applying it to the skin. The treatment’s new formulation was described in the European Journal of Pharmaceutics and Biopharmaceutics, in a study titled “Microemulsion-based gel for the…

Salivary Caffeine Levels Decreased in Some Patients

People with moderate or advanced Parkinson’s disease have abnormally low levels of caffeine in their saliva, despite normal caffeine metabolism, a new study indicates. The findings suggest that measuring caffeine in saliva could be useful for gauging Parkinson’s disease progression. The study, “Salivary caffeine in Parkinson’s…

STAR Candidates Boost GCase in Cell, Animal Models

Gain Therapeutics‘ investigational compounds were able to lessen motor symptoms in a rat model of GBA1-associated Parkinson’s disease and also decrease the levels of alpha-synuclein accumulation in nerve cells — two hallmarks of the neurodegenerative disease. The two candidates — GT-02287 and GT-02329 — are…

Partnership Seeks to Develop New Therapies

Alligator Bioscience and BioArctic AB have partnered to research and develop new therapies for neurodegenerative disorders such as Parkinson’s disease and Alzheimer’s. “We are very pleased that BioArctic has recognized the power of Alligator’s proprietary phage display libraries which have been successfully used to generate Alligator’s…